Arthritis

Once seen as an old-age condition, arthritis is now appearing in people in their 20s and 30s. Doctors say modern lifestyle habits are accelerating joint damage in young adults

As the national capital enters its harsh winter phase with plunging temperatures and thickening smog, physicians are sounding the alarm on a dual threat to joint health. Over the past two months, consultations for joint pain among patients with chronic arthritis have risen, although specific data quantifying the overall increase in joint cases across Delhi remains unavailable. A 2025 study published in the European Medical Journal found that long-term exposure to fine particulate matter (PM2.5) increases the risk of developing arthritis by 12 to 18 per cent, reinforcing concerns that poor air quality and cold weather together can significantly worsen joint pain and inflammation, according to orthopaedic specialists across the Delhi-NCR region. In many cases, the winter chill causes muscles around joints to tighten, blood flow to slow, and the tissues around the joint to contract. These factors are enough to worsen stiffness in patients and increase pain in patients with Osteoarthri

Should you reach for an ice pack or a hot compress? Experts explain how cold and heat therapies work differently and which one is best for your pain or injury

Phase 3 trials show ILUMYA improved PsA symptoms significantly, with no new safety concerns; results support potential regulatory submissions in the US and globally

From joint pain and cold weather to diet and exercise, doctors debunk 10 persistent myths about arthritis causes, treatment and prevention

MRI scans reveal early cartilage and bone damage in young adults, with obesity, high BMI and family history driving silent knee degeneration by age 30

BBL launched Hulio, a biosimilar version of Abbvie's blockbuster drug Humira, in the US in July

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose about 2% in premarket trading

Drug maker Lupin on Tuesday said its biosimilar product Rymti, indicated for the treatment of arthritis, has received approval from the Canadian health authority. The company's product is the biosimilar of reference drug Enbrel (Etanercept). The product is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis , plaque psoriasis and paediatric plaque psoriasis. "The approval for Rymti in Canada is a key milestone in our endeavours to improve access to medicines," Lupin Biotech President Cyrus Karkaria said in a statement. It underscores the scientific success of the company's biosimilar programmes and commitment to advancing healthcare through innovation, he added.

Osteoarthritis is common in older people, but it is possible for it to develop in younger people.

Drug firm Zydus Cadila said it has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market

The tablets will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said.

Some common symptoms of autoimmune diseases are pain in joints, stiffness, excessive tiredness and headaches

Current smokers are also 67% more likely to develop "seropositive" rheumatoid arthritis - when patients have antibodies in their blood that help identify the disease

The study found obesity and lack of awareness as leading factors contributing to its prevalence

Vitamin D levels may have an important role in the relationship between pain and sleep